Literature DB >> 26598514

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.

Christophe Le Tourneau1, Maud Kamal1, Apostolia-Maria Tsimberidou1, Philippe Bedard1, Gaëlle Pierron1, Céline Callens1, Etienne Rouleau1, Anne Vincent-Salomon1, Nicolas Servant1, Marie Alt1, Roman Rouzier1, Xavier Paoletti1, Olivier Delattre1, Ivan Bièche1.   

Abstract

With the advent of high-throughput molecular technologies, several precision medicine (PM) studies are currently ongoing that include molecular screening programs and PM clinical trials. Molecular profiling programs establish the molecular profile of patients' tumors with the aim to guide therapy based on identified molecular alterations. The aim of prospective PM clinical trials is to assess the clinical utility of tumor molecular profiling and to determine whether treatment selection based on molecular alterations produces superior outcomes compared with unselected treatment. These trials use treatment algorithms to assign patients to specific targeted therapies based on tumor molecular alterations. These algorithms should be governed by fixed rules to ensure standardization and reproducibility. Here, we summarize key molecular, biological, and technical criteria that, in our view, should be addressed when establishing treatment algorithms based on tumor molecular profiling for PM trials.
© The Author 2015. Published by Oxford University Press.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26598514      PMCID: PMC4830395          DOI: 10.1093/jnci/djv362

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  44 in total

1.  First FDA authorization for next-generation sequencer.

Authors:  Francis S Collins; Margaret A Hamburg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

Review 2.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

Authors:  D F Hayes; R C Bast; C E Desch; H Fritsche; N E Kemeny; J M Jessup; G Y Locker; J S Macdonald; R G Mennel; L Norton; P Ravdin; S Taube; R J Winn
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

3.  Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

Authors:  J Rodon; J C Soria; R Berger; G Batist; A Tsimberidou; C Bresson; J J Lee; E Rubin; A Onn; R L Schilsky; W H Miller; A M Eggermont; J Mendelsohn; V Lazar; R Kurzrock
Journal:  Ann Oncol       Date:  2015-04-23       Impact factor: 32.976

Review 4.  Implementing personalized cancer genomics in clinical trials.

Authors:  Richard Simon; Sameek Roychowdhury
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

5.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

6.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas.

Authors:  Chang-Hyuk Kwon; Dawen Zhao; Jian Chen; Sheila Alcantara; Yanjiao Li; Dennis K Burns; Ralph P Mason; Eva Y-H P Lee; Hong Wu; Luis F Parada
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

8.  Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.

Authors:  C Le Tourneau; X Paoletti; N Servant; I Bièche; D Gentien; T Rio Frio; A Vincent-Salomon; V Servois; J Romejon; O Mariani; V Bernard; P Huppe; G Pierron; F Mulot; C Callens; J Wong; C Mauborgne; E Rouleau; C Reyes; E Henry; Q Leroy; P Gestraud; P La Rosa; L Escalup; E Mitry; O Trédan; J-P Delord; M Campone; A Goncalves; N Isambert; C Gavoille; M Kamal
Journal:  Br J Cancer       Date:  2014-04-24       Impact factor: 7.640

9.  Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.

Authors:  Mariam Jamal-Hanjani; Alan Hackshaw; Yenting Ngai; Jacqueline Shaw; Caroline Dive; Sergio Quezada; Gary Middleton; Elza de Bruin; John Le Quesne; Seema Shafi; Mary Falzon; Stuart Horswell; Fiona Blackhall; Iftekhar Khan; Sam Janes; Marianne Nicolson; David Lawrence; Martin Forster; Dean Fennell; Siow-Ming Lee; Jason Lester; Keith Kerr; Salli Muller; Natasha Iles; Sean Smith; Nirupa Murugaesu; Richard Mitter; Max Salm; Aengus Stuart; Nik Matthews; Haydn Adams; Tanya Ahmad; Richard Attanoos; Jonathan Bennett; Nicolai Juul Birkbak; Richard Booton; Ged Brady; Keith Buchan; Arrigo Capitano; Mahendran Chetty; Mark Cobbold; Philip Crosbie; Helen Davies; Alan Denison; Madhav Djearman; Jacki Goldman; Tom Haswell; Leena Joseph; Malgorzata Kornaszewska; Matthew Krebs; Gerald Langman; Mairead MacKenzie; Joy Millar; Bruno Morgan; Babu Naidu; Daisuke Nonaka; Karl Peggs; Catrin Pritchard; Hardy Remmen; Andrew Rowan; Rajesh Shah; Elaine Smith; Yvonne Summers; Magali Taylor; Selvaraju Veeriah; David Waller; Ben Wilcox; Maggie Wilcox; Ian Woolhouse; Nicholas McGranahan; Charles Swanton
Journal:  PLoS Biol       Date:  2014-07-08       Impact factor: 8.029

10.  Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data.

Authors:  Valentina Boeva; Tatiana Popova; Maxime Lienard; Sebastien Toffoli; Maud Kamal; Christophe Le Tourneau; David Gentien; Nicolas Servant; Pierre Gestraud; Thomas Rio Frio; Philippe Hupé; Emmanuel Barillot; Jean-François Laes
Journal:  Bioinformatics       Date:  2014-07-12       Impact factor: 6.937

View more
  26 in total

Review 1.  Targeted therapies: What have we learned from SHIVA?

Authors:  Christophe Le Tourneau; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2016-10-11       Impact factor: 66.675

Review 2.  The evidence framework for precision cancer medicine.

Authors:  Jeffrey A Moscow; Tito Fojo; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2017-12-19       Impact factor: 66.675

3.  Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application.

Authors:  Gaye Lightbody; Valeriia Haberland; Fiona Browne; Laura Taggart; Huiru Zheng; Eileen Parkes; Jaine K Blayney
Journal:  Brief Bioinform       Date:  2019-09-27       Impact factor: 11.622

Review 4.  Precision Oncology: The Road Ahead.

Authors:  Daniela Senft; Mark D M Leiserson; Eytan Ruppin; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2017-09-05       Impact factor: 11.951

Review 5.  Strategies for Testing Intervention Matching Schemes in Cancer.

Authors:  Nicholas J Schork; Laura H Goetz; James Lowey; Jeffrey Trent
Journal:  Clin Pharmacol Ther       Date:  2020-07-24       Impact factor: 6.875

Review 6.  Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.

Authors:  John Paul Shen; Trey Ideker
Journal:  J Mol Biol       Date:  2018-06-20       Impact factor: 5.469

Review 7.  Human iPSC-derived neurons and lymphoblastoid cells for personalized medicine research in neuropsychiatric disorders.

Authors:  David Gurwitz
Journal:  Dialogues Clin Neurosci       Date:  2016-09       Impact factor: 5.986

8.  Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study.

Authors:  Sanne Samuels; Balazs Balint; Heiko von der Leyen; Philippe Hupé; Leanne de Koning; Choumouss Kamoun; Windy Luscap-Rondof; Ulrike Wittkop; Ksenia Bagrintseva; Marina Popovic; Atttila Kereszt; Els Berns; Gemma G Kenter; Ekaterina S Jordanova; Maud Kamal; Susy Scholl
Journal:  Br J Cancer       Date:  2016-11-22       Impact factor: 7.640

9.  Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey.

Authors:  Brenda F Kurland; Sameer Aggarwal; Thomas E Yankeelov; Elizabeth R Gerstner; James M Mountz; Hannah M Linden; Ella F Jones; Kellie L Bodeker; John M Buatti
Journal:  Tomography       Date:  2016-12

10.  Genomic insights into head and neck cancer.

Authors:  Tim N Beck; Erica A Golemis
Journal:  Cancers Head Neck       Date:  2016-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.